Storia in 2 fonti

Two biotechs sign reverse mergers to advance I&I drug, BTK inhibitor

Caldera-Synlogic and Vidya-Processa ink reverse mergers with Bain-backed placements, advancing a TL1A bispecific and a BTK inhibitor.

Raccontata da

biopharmadive.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo8 h fa

Two biotechs sign reverse mergers to advance I&I drug, BTK inhibitor

Caldera-Synlogic and Vidya-Processa ink reverse mergers with Bain-backed placements, advancing a TL1A bispecific and a BTK inhibitor.

originale

biopharmadive.com23 h fa

Caldera, Vidya add to recent flurry of biotech mergers

Caldera and Vidya merged with public biotech firms, raising $478M for drug candidates in inflammatory bowel disease and multiple sclerosis. Reverse mergers replace IPO for biotech market access; signals M&A consolidation trend for clinical-stage companies.

Leggi questa versione → originale

Timeline cronologica

mercoledì 29 luglio 2026·biopharmadive.com
Caldera, Vidya add to recent flurry of biotech mergers
The startups are part of a surge of young companies equipped with advanced drug prospects and quickly pivoting to the public markets.
mercoledì 29 luglio 2026·endpoints.news
Two biotechs sign reverse mergers to advance I&I drug, BTK inhibitor
Caldera-Synlogic and Vidya-Processa ink reverse mergers with Bain-backed placements, advancing a TL1A bispecific and a BTK inhibitor.